The combination of altered eating patterns, potential fluid loss, and metabolic adjustments may create conditions conducive to headache development
503B outsourcing facilities: FDA-registered facilities that may compound without individual prescriptions under Section 503B, subject to additional FDA oversight
In addition, GIP also plays a key role in metabolizing fat in foods
2 The addition of semaglutide to the Food and Drug Administration (FDA) shortage list from 2022 to February 2025, and tirzepatide to the same list from 2022 to December 2024, gave compounding pharmacies permission by the FDA to produce exact duplicates to ensure continuity of treatment until production met demand
However, it should be noted that combined with insulin may lead to hypoglycemia (94)
These compounds may help regulate various aspects of metabolism, appetite, and fat storage